-
Je něco špatně v tomto záznamu ?
Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients
O. Mayer, J. Bruthans, J. Seidlerová, J. Gelžinský, R. Kučera, P. Karnosová, M. Mateřánková, M. Rychecká, P. Wohlfahrt, R. Cífková, J. Filipovský, C. Vermeer
Jazyk angličtina Země Velká Británie
Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, práce podpořená grantem
NLK
PubMed Central
od 2015 do Před 1 rokem
ProQuest Central
od 2007-06-01 do 2021-01-31
Health & Medicine (ProQuest)
od 2007-06-01 do 2021-01-31
Public Health Database (ProQuest)
od 2007-06-01 do 2021-01-31
PubMed
34668399
DOI
10.2217/bmm-2021-0168
Knihovny.cz E-zdroje
- MeSH
- adaptorové proteiny signální transdukční krev MeSH
- koronární nemoc krev mortalita MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- prospektivní studie MeSH
- rizikové faktory MeSH
- senioři MeSH
- vitamin K krev MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
Aim: We explored whether matrix Gla protein (MGP, natural calcification inhibitor) and sclerostin (glycoprotein responsible for osteoblast differentiation) interact in terms of mortality risk in coronary patients. Methods: 945 patients after myocardial infarction and/or coronary revascularization were followed in a prospective study. All-cause death, fatal or nonfatal cardiovascular events and heart failure hospitalizations were registered. Results: Either high desphospho-uncarboxylated MGP (dp-ucMGP) or high sclerostin were independently associated with 5-year all-cause/cardiovascular mortality. However, we observed an additional mortality risk in the coincidence of both factors. Concomitantly high dp-ucMGP (≥884 pmol/l) plus sclerostin (≥589 ng/l) were associated with increased all-cause mortality risk compared with 'normal' concentrations of both factors (HRR 3.71 [95% CI: 2.07-6.62, p < 0.0001]), or if only one biomarker has been increased. A similar pattern was observed for fatal, but not for nonfatal cardiovascular events. Conclusion: Concomitantly high MGP and sclerostin indicate increased mortality risk, which probably reflects their role in cardiovascular calcifications.
Biomedical Center Medical Faculty of Charles University Pilsen 301 00 Czech Republic
Cardiovascular Research Institute CARIM Maastricht University Maastricht 6200 The Netherlands
Department of Immunochemistry Diagnostics University Hospital Pilsen 301 00 Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011965
- 003
- CZ-PrNML
- 005
- 20250325142640.0
- 007
- ta
- 008
- 220425s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2217/bmm-2021-0168 $2 doi
- 035 __
- $a (PubMed)34668399
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Mayer, Otto $u Second Department of Internal Medicine, Medical Faculty of Charles University & University Hospital, Pilsen, 301 00, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, 301 00, Czech Republic $1 https://orcid.org/0000000280233749
- 245 10
- $a Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients / $c O. Mayer, J. Bruthans, J. Seidlerová, J. Gelžinský, R. Kučera, P. Karnosová, M. Mateřánková, M. Rychecká, P. Wohlfahrt, R. Cífková, J. Filipovský, C. Vermeer
- 520 9_
- $a Aim: We explored whether matrix Gla protein (MGP, natural calcification inhibitor) and sclerostin (glycoprotein responsible for osteoblast differentiation) interact in terms of mortality risk in coronary patients. Methods: 945 patients after myocardial infarction and/or coronary revascularization were followed in a prospective study. All-cause death, fatal or nonfatal cardiovascular events and heart failure hospitalizations were registered. Results: Either high desphospho-uncarboxylated MGP (dp-ucMGP) or high sclerostin were independently associated with 5-year all-cause/cardiovascular mortality. However, we observed an additional mortality risk in the coincidence of both factors. Concomitantly high dp-ucMGP (≥884 pmol/l) plus sclerostin (≥589 ng/l) were associated with increased all-cause mortality risk compared with 'normal' concentrations of both factors (HRR 3.71 [95% CI: 2.07-6.62, p < 0.0001]), or if only one biomarker has been increased. A similar pattern was observed for fatal, but not for nonfatal cardiovascular events. Conclusion: Concomitantly high MGP and sclerostin indicate increased mortality risk, which probably reflects their role in cardiovascular calcifications.
- 650 _2
- $a adaptorové proteiny signální transdukční $x krev $7 D048868
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a koronární nemoc $x krev $x mortalita $7 D003327
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a vitamin K $x krev $7 D014812
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Bruthans, Jan $u Second Department of Internal Medicine, Medical Faculty of Charles University & University Hospital, Pilsen, 301 00, Czech Republic $u Centre for Cardiovascular Prevention, First Faculty of Medicine, Charles, University & Thomayer Hospital, Prague, 140 00, Czech Republic
- 700 1_
- $a Seidlerová, Jitka $u Second Department of Internal Medicine, Medical Faculty of Charles University & University Hospital, Pilsen, 301 00, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, 301 00, Czech Republic
- 700 1_
- $a Gelžinský, Julius $u Second Department of Internal Medicine, Medical Faculty of Charles University & University Hospital, Pilsen, 301 00, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, 301 00, Czech Republic
- 700 1_
- $a Kučera, Radek $u Department of Immunochemistry Diagnostics, University Hospital, Pilsen, 301 00, Czech Republic
- 700 1_
- $a Karnosová, Petra, $u Second Department of Internal Medicine, Medical Faculty of Charles University & University Hospital, Pilsen, 301 00, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, 301 00, Czech Republic $d 1985- $7 xx0330667
- 700 1_
- $a Mateřánková, Markéta $u Second Department of Internal Medicine, Medical Faculty of Charles University & University Hospital, Pilsen, 301 00, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, 301 00, Czech Republic
- 700 1_
- $a Rychecká, Martina $u Second Department of Internal Medicine, Medical Faculty of Charles University & University Hospital, Pilsen, 301 00, Czech Republic
- 700 1_
- $a Wohlfahrt, Peter $u Centre for Cardiovascular Prevention, First Faculty of Medicine, Charles, University & Thomayer Hospital, Prague, 140 00, Czech Republic
- 700 1_
- $a Cífková, Renata $u Centre for Cardiovascular Prevention, First Faculty of Medicine, Charles, University & Thomayer Hospital, Prague, 140 00, Czech Republic
- 700 1_
- $a Filipovský, Jan $u Second Department of Internal Medicine, Medical Faculty of Charles University & University Hospital, Pilsen, 301 00, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, 301 00, Czech Republic
- 700 1_
- $a Vermeer, Cees $u Cardiovascular Research Institute CARIM, Maastricht University, Maastricht, 6200, The Netherlands
- 773 0_
- $w MED00172897 $t Biomarkers in medicine $x 1752-0371 $g Roč. 15, č. 16 (2021), s. 1465-1477
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34668399 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20250325142640 $b ABA008
- 999 __
- $a ok $b bmc $g 1789514 $s 1163166
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 15 $c 16 $d 1465-1477 $e 20211020 $i 1752-0371 $m Biomarkers in medicine $n Biomark Med $x MED00172897
- LZP __
- $a Pubmed-20220425
